ReLive: investigators meeting and E-poster of the study design during the 2015 EASL congress -ReLive: Investigator-møde og e-poster om studiets design under 2015 EASL-kongressen

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that  an investigators’ meeting (on April 24, 2015) will be held during the 50th annual meeting of the European Association for the Study of the Liver (EASL) taking place in Vienna (Austria) from April 22 to April 26, 2015, with ReLive investigators.

The EASL was founded almost 50 years ago to promote and exchange science in the field of liver diseases. Its annual meeting involves the specialists of hepatology and liver cancer and is therefore a choice opportunity to gather the European and US investigators of the ReLive clinical trial who will attend the congress.

At this occasion, an investigators meeting  will take place with the clinicians involved in ReLive trial in order to review study advancement, share views and allow open discussions.

Besides, the ReLive study design,  Livatag® phase III clinical trial, will be published as an e-poster during the 50th annual meeting of the European Association for the Study of the Liver (EASL), enhancing the awareness of the scientific community about ReLive and Livatag®.

ReLive Poster EASL

150416EN_Livatag EASL

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), et innovativt selskab med speciale i udvikling af lægemidler til behandling af sjældne kræftsygdomme, har i dag meddelt, at der vil blive afholdt et møde med “ReLive”-studiets investigatorer (den 24. april 2015) under det 50. årsmøde i European Association for the Study of the Liver (EASL), som finder sted i Wien, Østrig, fra 22. til 26. april 2015.

EASL blev grundlagt for knap 50 år siden med henblik på at øge kendskabet til og dele viden om leversygdomme. Årsmødet i EASL har deltagelse af specialister inden for hepatologi og leverkræft, og det er således en god mulighed for at samle de europæiske og amerikanske investigatorer i det kliniske “ReLive”-studie, som deltager i kongressen.

Ved denne begivenhed vil der blive afholdt et investigator-møde med de klinikere, der er involveret i “ReLive”-studiet med henblik på at gennemgå studiets fremskridt, dele synspunkter og føre en åben drøftelse.

Derudover vil designet af “ReLive”-studiet (Livatag® i klinisk fase III) blive offentliggjort som en e-poster under det 50. årsmøde i European Association for the Study of the Liver (EASL) for derved at øge forskningsverdenens kendskab til “ReLive” og Livatag®.

ReLive Poster EASL

150416DK_Livatag_EASL